Phase 2 Schizophrenia Trial, Recruiting NCT05770375 Sponsor: Anya Bershad, MD, PhD Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT05770375
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 60 years old
  • People who can understand spoken English well enough to follow the testing procedures
  • People who have been diagnosed with schizophrenia (based on the DSM-5 criteria, confirmed through a clinical interview)
  • People who have been clinically stable — meaning no hospital stays for psychiatric reasons in the past 6 months, and no changes to their psychiatric medication in the past 6 months

Who may not be able to join:

  • People with a history of aggressive or suicidal behaviour during a psychotic episode
  • People with a history of an IQ below 70 or a developmental disability, based on their medical history
  • People with a significant neurological condition (such as epilepsy) or a significant heart condition (such as an irregular heartbeat), based on their medical history
  • People with a history of a serious head injury — for example, losing consciousness for more than an hour, lasting thinking or memory problems after a head injury, or having received cognitive rehabilitation after a head injury
  • People who have had a substance use disorder or alcohol use disorder in the past six months
  • People who have taken sedatives or benzodiazepines (a type of calming medication) within 24 hours before testing
  • People whose urine test comes back positive for drugs, or who appear visibly intoxicated on the day of assessment
  • People who are pregnant or think they may be pregnant, based on self-report and a urine test
  • People who are currently taking SSRIs or SNRIs (certain types of antidepressant medications)
  • People with a history of Neuroleptic Malignant Syndrome (NMS) or serotonin syndrome (serious reactions to certain medications) (confirm with trial site)
  • People whose heart trace (ECG) shows a specific abnormality called a prolonged QTc interval (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 310-794-5577

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Anya Bershad, MD, PhD
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Positive and Negative Syndrome Scale for Schizophrenia (PANSS): Disorganized speech.; Positive and Negative Syndrome Scale for Schizophrenia (PANSS): Delusions; Positive and Negative Syndrome Scale for Schizophrenia (PANSS): Hallucinations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov